EP2807167A1 - Dérivés d'isoquinuclidène réunis par fusion à de l'indole et du benzofurane et leurs procédés de préparation - Google Patents
Dérivés d'isoquinuclidène réunis par fusion à de l'indole et du benzofurane et leurs procédés de préparationInfo
- Publication number
- EP2807167A1 EP2807167A1 EP13741381.1A EP13741381A EP2807167A1 EP 2807167 A1 EP2807167 A1 EP 2807167A1 EP 13741381 A EP13741381 A EP 13741381A EP 2807167 A1 EP2807167 A1 EP 2807167A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- compound
- alkyl
- formula
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title abstract description 62
- 230000008569 process Effects 0.000 title abstract description 39
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title abstract description 20
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 title abstract description 16
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 title abstract description 10
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 title abstract description 10
- RAUCDOKTMDOIPF-RYRUWHOVSA-N noribogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(O)C=C12 RAUCDOKTMDOIPF-RYRUWHOVSA-N 0.000 claims abstract description 39
- 150000003839 salts Chemical class 0.000 claims abstract description 33
- RAUCDOKTMDOIPF-UHFFFAOYSA-N hydroxyibogamine Natural products CCC1CC(C2)CC3C1N2CCC1=C3NC2=CC=C(O)C=C12 RAUCDOKTMDOIPF-UHFFFAOYSA-N 0.000 claims abstract description 26
- 150000001875 compounds Chemical class 0.000 claims description 121
- -1 amino, hydroxy Chemical group 0.000 claims description 72
- 125000003118 aryl group Chemical group 0.000 claims description 29
- 125000001424 substituent group Chemical group 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 26
- 150000002148 esters Chemical class 0.000 claims description 24
- 229930194542 Keto Natural products 0.000 claims description 22
- 125000000468 ketone group Chemical group 0.000 claims description 22
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 20
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 15
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- AREITJMUSRHSBK-UHFFFAOYSA-N ibogamine Natural products CCC1CC2C3CC1CN2CCc4c3[nH]c5ccccc45 AREITJMUSRHSBK-UHFFFAOYSA-N 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 7
- VOXIUXZAOFEFBL-UHFFFAOYSA-N Voacangin Natural products CCC1CC2CN3CC1C(C2)(OC(=O)C)c4[nH]c5ccc(OC)cc5c4C3 VOXIUXZAOFEFBL-UHFFFAOYSA-N 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 125000004122 cyclic group Chemical group 0.000 claims description 7
- HSIBGVUMFOSJPD-CFDPKNGZSA-N ibogaine Chemical group N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(OC)C=C12 HSIBGVUMFOSJPD-CFDPKNGZSA-N 0.000 claims description 7
- OLOCMRXSJQJJPL-UHFFFAOYSA-N ibogaine Natural products CCC1CC2CC3C1N(C2)C=Cc4c3[nH]c5ccc(OC)cc45 OLOCMRXSJQJJPL-UHFFFAOYSA-N 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- LRLCVRYKAFDXKU-YGOSVGOTSA-N ibogamine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=CC=C12 LRLCVRYKAFDXKU-YGOSVGOTSA-N 0.000 claims description 5
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- VLOWUTVRYMTRJO-HHNICDRHSA-N 12,13-dimethoxyibogamine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC(OC)=C(OC)C=C12 VLOWUTVRYMTRJO-HHNICDRHSA-N 0.000 claims description 3
- 239000002262 Schiff base Substances 0.000 claims description 2
- 150000004753 Schiff bases Chemical class 0.000 claims description 2
- 125000002573 ethenylidene group Chemical group [*]=C=C([H])[H] 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 10
- 150000002431 hydrogen Chemical group 0.000 claims 4
- 238000006243 chemical reaction Methods 0.000 description 49
- 239000000047 product Substances 0.000 description 40
- 238000000746 purification Methods 0.000 description 25
- 239000002585 base Substances 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 239000003054 catalyst Substances 0.000 description 15
- 238000005481 NMR spectroscopy Methods 0.000 description 14
- 238000002425 crystallisation Methods 0.000 description 14
- 230000008025 crystallization Effects 0.000 description 14
- 239000012442 inert solvent Substances 0.000 description 14
- 239000002253 acid Substances 0.000 description 13
- 125000005843 halogen group Chemical group 0.000 description 13
- 238000004811 liquid chromatography Methods 0.000 description 13
- 238000001556 precipitation Methods 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 238000004809 thin layer chromatography Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 238000005984 hydrogenation reaction Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 229940125782 compound 2 Drugs 0.000 description 9
- 238000010511 deprotection reaction Methods 0.000 description 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 8
- 239000002841 Lewis acid Substances 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 229940126214 compound 3 Drugs 0.000 description 8
- 150000007517 lewis acids Chemical class 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 239000007800 oxidant agent Substances 0.000 description 7
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 229930013930 alkaloid Natural products 0.000 description 6
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 229910015900 BF3 Inorganic materials 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 241001246918 Tabernanthe iboga Species 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 239000003513 alkali Substances 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 5
- 229940125898 compound 5 Drugs 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- 238000006783 Fischer indole synthesis reaction Methods 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 150000001993 dienes Chemical class 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 125000001183 hydrocarbyl group Chemical group 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000010626 work up procedure Methods 0.000 description 4
- MMAYTCMMKJYIAM-RUGRQLENSA-N (-)-voacangine Chemical compound C([C@H]1C[C@@H]([C@H]2[C@]3(C1)C(=O)OC)CC)N2CCC1=C3NC2=CC=C(OC)C=C12 MMAYTCMMKJYIAM-RUGRQLENSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- 239000007848 Bronsted acid Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 125000006242 amine protecting group Chemical group 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000003709 fluoroalkyl group Chemical group 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 150000004678 hydrides Chemical class 0.000 description 3
- 150000004679 hydroxides Chemical class 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000012011 nucleophilic catalyst Substances 0.000 description 3
- 230000000269 nucleophilic effect Effects 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 229940067157 phenylhydrazine Drugs 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000010948 rhodium Substances 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 229940086542 triethylamine Drugs 0.000 description 3
- CKWXDLJHOHJWOX-UHFFFAOYSA-N voacangine hydroxyindolenine Natural products CCC1CC2N3CCC4(O)C(=Nc5ccc(OC)cc45)C2(CC1C3)C(=O)OC CKWXDLJHOHJWOX-UHFFFAOYSA-N 0.000 description 3
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 2
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 2
- RGUKYNXWOWSRET-UHFFFAOYSA-N 4-pyrrolidin-1-ylpyridine Chemical compound C1CCCN1C1=CC=NC=C1 RGUKYNXWOWSRET-UHFFFAOYSA-N 0.000 description 2
- SCEMXAFQSIHIMR-UHFFFAOYSA-N 5-azabicyclo[2.2.2]oct-2-en-8-one Chemical compound C1NC2C(=O)CC1C=C2 SCEMXAFQSIHIMR-UHFFFAOYSA-N 0.000 description 2
- 229910015845 BBr3 Inorganic materials 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 238000005698 Diels-Alder reaction Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 238000006617 Intramolecular Heck reaction Methods 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 229910017912 NH2OH Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- UCIDWKVIQZIKEK-NXWOVTFFSA-N Tabernanthine Chemical group N1([C@@H]2[C@H]3C[C@@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC(OC)=CC=C12 UCIDWKVIQZIKEK-NXWOVTFFSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical class C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 150000004031 phenylhydrazines Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229910052703 rhodium Inorganic materials 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- UCIDWKVIQZIKEK-UHFFFAOYSA-N tabernanthine Natural products CCC1CC(C2)CC3C1N2CCC1=C3NC2=CC(OC)=CC=C12 UCIDWKVIQZIKEK-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- PPTXVXKCQZKFBN-UHFFFAOYSA-N (S)-(-)-1,1'-Bi-2-naphthol Chemical compound C1=CC=C2C(C3=C4C=CC=CC4=CC=C3O)=C(O)C=CC2=C1 PPTXVXKCQZKFBN-UHFFFAOYSA-N 0.000 description 1
- KWEKXPWNFQBJAY-UHFFFAOYSA-N (dimethyl-$l^{3}-silanyl)oxy-dimethylsilicon Chemical compound C[Si](C)O[Si](C)C KWEKXPWNFQBJAY-UHFFFAOYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- ASFBWGBRGNINAE-UHFFFAOYSA-N 2-(5-phenylmethoxy-1h-indol-2-yl)acetic acid Chemical compound C=1C=C2NC(CC(=O)O)=CC2=CC=1OCC1=CC=CC=C1 ASFBWGBRGNINAE-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical class NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229910004664 Cerium(III) chloride Inorganic materials 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 229910000086 alane Inorganic materials 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 125000000746 allylic group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical class O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- VYLVYHXQOHJDJL-UHFFFAOYSA-K cerium trichloride Chemical compound Cl[Ce](Cl)Cl VYLVYHXQOHJDJL-UHFFFAOYSA-K 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- JOPOVCBBYLSVDA-UHFFFAOYSA-N chromium(6+) Chemical compound [Cr+6] JOPOVCBBYLSVDA-UHFFFAOYSA-N 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229910052593 corundum Inorganic materials 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- SOCTUWSJJQCPFX-UHFFFAOYSA-N dichromate(2-) Chemical compound [O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O SOCTUWSJJQCPFX-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000002803 fossil fuel Substances 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003617 indole-3-acetic acid Substances 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000005907 ketalization reaction Methods 0.000 description 1
- 239000004310 lactic acid Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical class C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- WXHIJDCHNDBCNY-UHFFFAOYSA-N palladium dihydride Chemical class [PdH2] WXHIJDCHNDBCNY-UHFFFAOYSA-N 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003385 ring cleavage reaction Methods 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 239000003579 shift reagent Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000011975 tartaric acid Chemical class 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical class C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- WILBTFWIBAOWLN-UHFFFAOYSA-N triethyl(triethylsilyloxy)silane Chemical compound CC[Si](CC)(CC)O[Si](CC)(CC)CC WILBTFWIBAOWLN-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910001845 yogo sapphire Inorganic materials 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Definitions
- indole and benzofuran fused isoquinuclidene derivatives and processes, preferably enantioselective processes, for preparing such derivatives including processes for preparing (-) and (+) noribogaine, in substantially
- this invention provides (-) or (+) noribogaine or a salt, preferably a pharmaceutically acceptable salt, of each thereof, preferably in a substantially enantiomerically pure form, prepared according to the processes provided herein, and also provides pharmaceutical compositions comprising (-) noribogaine or a salt thereof thus prepared.
- Noribogaine is a well known compound whose structure combines the features, for example, of tyrptamine, and isoquinuclidene.
- the naturally occurring enantiomer of noribo aine can be depicted by the following formula:
- the naturally occurring enantiomer of noribogaine is prepared by O-demethylation of naturally occurring ibogaine or prepared by
- Voacangine and Ibogaine are obtained from plants where both the supply is limited and the quality of the supply is unpredictable.
- indole and benzofuran fused isoquinuclidene derivatives and processes, preferably enantioselective processes, for preparing such derivatives including processes for preparing (-) or (+) noribogaine or a salt thereof, in substantially enantiomerically pure forms.
- the processes provided herein employ the novel 1R,4R 7-oxo- 2-azabicyclo[2.2.2]oct-5-ene or a protected derivative thereof.
- this invention provides (-) noribogaine or a salt, preferably a pharmaceutically acceptable salt, thereof, preferably in a substantially enantiomerically pure form, prepared according to the processes provided herein.
- this invention provides a composition comprising the (-) noribogaine or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.
- This invention also provides processes for preparing (+) noribogaine.
- pharmaceutically acceptable refers to a safe and non-toxic composition, which is suitable for in vivo, preferably for human administration.
- FIG. 1 illustrates a 1H-NMR spectrum in CDC1 3 of compound 3 :
- FIG. 2 illustrates a 1H-NMR s ectrum in CDC1 3 of compound 1 :
- FIG. 3 illustrates a 1H- MR spectrum in CDCI 3 of compound 2:
- indole and benzofuran fused isoquinuclidene derivatives and processes, preferably enantioselective processes, for preparing such derivatives including processes for preparing (-) and (+) noribogaine or a salt of each thereof, in substantially enantiomerically pure forms.
- alkenyl refers to hydrocarbyl groups having from 2 to 10 carbon atoms and at least one and up to 3 carbon carbon double bonds. Examples of alkenyl include vinyl, allyl, dimethyl allyl, and the like.
- alkoxy refers to -O-alkyl
- alkyl refers to hydrocarbyl groups having from 1 to 10 carbon atoms, more preferably 1 to 6 carbon atoms, and still more preferably 1-4 carbon atoms.
- the alkyl group may contain linear or branched carbon chains. This term is exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, n-pentyl, n-decyl and the like.
- alkynyl refers to hydrocarbyl groups having from 2 to 10 carbon atoms and at least one and up to 2 carbon carbon triple bonds. Examples of alkynyl include ethynyl, propargyl, dimethylpropargyl, and the like.
- amino refers to -NR x R y wherein each R x and R y
- aryl refers to an aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl) which condensed rings may or may not be aromatic (e.g., 2- benzoxazolinone, 2H-l,4-benzoxazin-3(4H)-one-7-yl, and the like) provided that the point of attachment is at an aromatic carbon atom.
- aryl refers to an aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl) which condensed rings may or may not be aromatic (e.g., 2- benzoxazolinone, 2H-l,4-benzoxazin-3(4H)-one-7-yl, and the like) provided that the point of attachment is at
- base refers to a compound that can accept a proton or donate a lone electron pair.
- bases include, alkali (OH ), carbonate, bicarbonate, alkoxides (alkyl-OQ), hydrides (alkali metal hydrides and CaH 2 ), amides (NH 2 ( ⁇ ), R ⁇ H ⁇ ), or (R b ) 2 N( ⁇ ), wherein R b is alkyl or 2 R b s together with the nitrogen form a 5-6 membered ring), and neutral nitrogen containing bases such as (R b ) 3 N, pyridine, 4-N,N- dialkylpyridine, and the like.
- nucleophilic bases refer to preferably neutral nitrogen containing bases that can catalyze the addition of an acyl halide or a sulfonyl halide(such as R b COX or R b S0 2 X) to an -OH, -NH 2 , or an -NHR b group.
- Preferred examples include, 4-N,N-dialkylpyridines.
- a “Bronsted acid” refers to a compound that can donate a proton.
- chlorinated solvent refers to chlorinated methane and ethane, which are preferably trichlorinated, and more preferably dichlorinated. Yet more preferably, the chlorinated solvent is dihloromethane.
- compositions and methods are intended to mean that the compositions and methods include the recited elements, but not excluding others.
- Consisting essentially of when used to define compositions and methods shall mean excluding other elements of any essential significance to the combination for the stated purpose. Thus, a composition consisting essentially of the elements as defined herein would not exclude other materials or steps that do not materially affect the basic and novel characteristic(s) of the claimed invention.
- Consisting of shall mean excluding more than trace elements of other ingredients and substantial method steps. Embodiments defined by each of these transition terms are within the scope of this invention.
- cycloalkyl refers to cyclic hydrocarbyl groups of from 3 to 10 carbon atoms having single or multiple condensed rings, which condensed rings may be aromatic or contain a heteroatom, provided that the point of attachment is at a cycloalkyl carbon atom.
- Cycloalkyl includes, by way of example, adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl and the like. Cycloalkyl rings are preferably saturated, though, cycloalkyl rings including 1-2 carbon carbon double bonds are also contemplated provided that the ring is not aromatic.
- C x refers to a group having x carbon atoms, wherein x is an integer, for example, C 4 alkyl refers to an alkyl group having 4 carbon atoms.
- ee refers to enantiomeric excess and is expressed as (e -e )%
- e and e are the two enantiomers.
- e and e are the two enantiomers.
- the e 1 enantiomer is present in an ee of 90%.
- the ee of an enantiomer in a mixture of enantiomers is determined following various methods well known to the skilled artisan, such as using chiral lanthanide based nuclear magnetic resonance shift reagents, forming derivatives with chiral compounds such as chiral hydroxyacids, amino acids, and the like.
- Various physical measurements such as circular dichroism, optical rotation, etc. are also useful in determining the ee of a mixture of enantiomers.
- deprotection condition refers to reaction conditions that transform a phenolic ether to the corresponding phenol and includes reacting with various Lewis acids such as BBr 3 , and when the alkyl group in the ether is a methyl group containing at least one phenyl or substituted phenyl group, reacting under hydrogenation conditions.
- -C0 2 H “ester” refers to -C0 2 R E wherein R E is selected from the group consisting of C 6 -Cio aryl and Ci-C 6 alkyl optionally substituted with 1-3 C 6 -Cio aryl groups.
- Fischer indole synthesis condition refers to reaction conditions for reacting phenylhydrazine with a ketone containing at least one a-methylene group and an acid to provide an indole derivative.
- Bronsted acids such as HC1, H 2 S0 4 , polyphosphoric acid and p-toluenesulfonic acid are useful, as are Lewis acids such as boron trifluoride, zinc chloride, iron chloride, and aluminum chloride.
- fluoroalkyl refers to an alkyl group substituted with up to 5, or preferably up to 3 fluoro groups.
- halo refers to F, CI, Br, or I.
- heteroaryl refers to an aromatic group of from 1 to 10 carbon atoms and 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen, sulfur within the ring, wherein the nitrogen and/or sulfur atom(s) of the heteroaryl are optionally oxidized (e.g., N-oxide, -S(O)- or -S(0) 2 -), provided that the ring has at least 5 ring atoms and up to 14, or preferably from 5-10, ring atoms.
- heteroaryl groups can have a single ring (e.g., pyridyl or furyl) or multiple condensed rings (e.g., indolizinyl or benzothienyl) wherein the condensed rings may or may not be aromatic and/or contain a heteroatom provided that the point of attachment is through an atom of the aromatic heteroaryl group.
- heteroaryls include pyridyl, pyrrolyl, indolyl, thiophenyl, furyl, and the like.
- heterocyclyl refers to a cycloalkyl group of from 1 to 10 carbon atoms and 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen, sulfur within the ring, wherein the nitrogen and/or sulfur atom(s) of the heteroaryl are optionally oxidized (e.g., N-oxide, -S(O)- or -S(0) 2 -), provided that the ring has at least 3 and up to 14, or preferably from 5-10 ring atoms.
- heterocyclyl groups can have a single ring or multiple condensed rings wherein the condensed rings may not contain a heteroatom and/or may contain an aryl or a heteroaryl moiety, provided that the point of attachment is through an atom of the non-aromatic heterocyclyl group.
- heterocyclyl include pyrrolidinyl, piperadinyl, piperazinyl, and the like.
- Heterocyclyl rings are preferably saturated, though, heterocyclyl rings including 1-2 carbon carbon double bonds are also contemplated provided that the ring is not aromatic.
- hydrogenation conditions refer to conditions including hydrogen gas at atmospheric or higher pressure and catalysts that catalyze the reaction of the hydrogen with a hydrogen reactive group, such as a benzyl group or a carbon carbon double/triple bond.
- Catalysts useful for hydrogenation include palladium, platinum, and rhodium metals and their oxides or hydroxides, preferably supported on a material such as carbon or alumina.
- protecting group refers to well known functional groups which, when bound to a functional group, render the resulting protected functional group inert to the reaction to be conducted on other portions of the compound and the corresponding reaction condition, and which can be reacted to regenerate the original functionality under deprotection conditions.
- the protecting group is selected to be compatible with the remainder of the molecule.
- the protecting group is an "amine protecting group” which protects an -NH- or an -NH 2 - moiety, for example during the syntheses described here.
- amine protecting groups include, for instance, benzyl, acetyl, oxyacetyl, carbonyloxybenzyl (Cbz), Fmoc, and the like.
- the protecting group is a "hydroxy protecting group" which protects a hydroxyl functionality during the synthesis described here.
- hydroxyl protecting groups include, for instance, benzyl, p-methoxybenzyl, p-nitrobenzyl, allyl, trityl, dialkylsilylethers, such as dimethylsilyl ether, and trialkylsilyl ethers such as trimethylsilyl ether, triethylsilyl ether, and t-butyldimethylsilyl ether; esters such as benzoyl, acetyl, phenylacetyl, formyl, mono-, di-, and trihaloacetyl such as chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl; and carbonates such as methyl, ethyl, 2,2,2-trichloroethyl, allyl, and benzyl.
- dialkylsilylethers such as dimethylsilyl ether
- trialkylsilyl ethers such as
- amine protecting groups are also useful as amine protecting groups. Additional examples of amine, hydroxy, and keto protecting groups are found in standard reference works such as Greene and Wuts, Protective Groups in Organic Synthesis., 2d Ed., 1991, John Wiley & Sons, and McOmie Protective Groups in Organic Chemistry, 1975, Plenum Press. Methods for protecting and deprotecting hydroxyl, -NH-, -NH 2 -, and keto groups disclosed herein can be found in the art, and specifically in Greene and Wuts, supra, and the references cited therein.
- a "Lewis acid” refers to a compound that can donate a lone electron pair.
- non nucleophilic base refers to a base that is capable of abstracting an acidic hydrogen, e.g., from an -OH or -NH- moiety, but does not readily take part in a nucleophilic substitution reaction.
- bases are metal hydrides such as alkali metal hydridies or Ca3 ⁇ 4.
- oxidizing agent refers to a compound that can accept electrons, and e.g., convert a CH(OH) group to a keto group.
- oxidizing agents are well known, and non limiting examples include hexavalent chromium reagents such as pyridinium chlorochromate, pyridinium dichromate, hypervalent iodine, and hypochlorite.
- reducing agent refers to a compounds that can donate electrons or a hydride in a reaction.
- Preferred examples include borohydrides such as NaBH 4 /CeCl 3 , and alanes such as diisobutyl aluminum hydride.
- a salt refers to preferably a salt of a mineral acid, or an organic acid such as a carboxylic acid or a sulfonic acid, and/or to alkali, alkaline earth, and various ammonium (including tetraalkyl ammonium, pyridinum, imidazolium and the like) salts.
- acid salts include salts of hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, methane sulfonic acid, phosphorous acid, nitric acid, perchloric acid, acetic acid, tartaric acid, lactic acid, succinic acid, and citric acid.
- ((S)-binol) refers to the (S)-enantiomer of 1 , 1 '-bi-2- naphthol
- ((R)-binol) refers to the (R)-enantiomer of l,l'-bi-2-naphthol.
- sil refers to Si(R z ) 3 wherein each R z independently is Ci-C 6 alkyl or C 6 -Cio aryl.
- substantially enantiomerically enriched refers to an enantiomer in an enantiomeric mixture with at least 95% ee, preferably 98% ee, or more preferably 99% ee.
- this invention provides compounds of Formulas (I) and (VI):
- k is 1, 2, or 3;
- each R 1 is independently selected from the group consisting of hydrogen, halo, amino, hydroxy, Ci-C 6 alkoxy, Ci-C 6 alkyl, C 2 -C6 alkenyl, C 2 -C6 alkynyl, cyano, nitro, - N 3 , and -C0 2 H or an ester thereof, wherein the alkyl, alkoxy, alkenyl, or the alkylnyl group is optionally substituted with 1-3 substituents selected from the group consisting of keto, halo, amino, hydroxy, cyano, nitro, -N 3 , phenyl optionally substituted with 1-3 substituents selected from the group consisting of Ci-C 6 alkyl and Ci-C 6 alkoxy, and - C0 2 H or an ester thereof;
- R is hydrogen or C(R ) 2 is a keto group
- R is selected from the group consisting of hydrogen, halo, Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, wherein the alkyl, alkenyl, or the alkylnyl group is optionally substituted with 1-3 substituents selected from the group consisting of keto, halo, amino, hydroxy, cyano, nitro, -N 3 , and -C0 2 H or an ester thereof;
- each R is independently selected from the group consisting of Ci-C 6 alkyl optionally substituted with 1-3 substituents selected from the group consisting of C 6 -Cio aryl, C 3 -C 8 cycloalkyl, C2-C10 heteroaryl, C 3 -C 8 heterocyclyl, halo, amino, -N 3 , hydroxy, Ci-C 6 alkoxy, silyl, nitro, cyano, and C0 2 H or an ester thereof, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 6 -Cio aryl, C 2 -Cio heteroaryl, C 3 -C 8 cycloalkyl, and C 3 -C 8 heterocyclyl;
- each R is independently selected from the group consisting of Ci-C 6 alkyl optionally substituted with 1-3 substituents selected from the group consisting of C 6 -Cio aryl, C 3 -C 8 cycloalkyl, C2-C10 heteroaryl, C 3 -C 8 heterocyclyl, halo, amino, -N 3 , hydroxy, Ci-C alkoxy, silyl, nitro, cyano, and C0 2 H or an ester thereof, C 2 -C 6 alkenyl, and C 2 -C 6 alkynyl;
- X in both occurrences is either oxygen or sulfur
- n 1 , 2, 3, or 4;
- n 1 or 2;
- R 43 is selected from the group consisting of C 6 -Cio aryl and C 2 -Cio heteroaryl; R is selected from the group consisting of Ci-C 6 alkyl and C 6 -Cio aryl;
- R is hydrogen, Ci-C 6 alkyl, C 2 -C6 alkenyl, and C 2 -C 6 alkynyl, wherein the alkyl, alkenyl, or the alkynyl group is optionally substituted with 1-3 substituents selected from the group consisting of keto, Ci-C 6 alkoxy, amino, hydroxy, cyano, nitro, -NHCOCH 3 , and -C0 2 H or an ester thereof;
- R 49 is hydrogen or Ci-C 6 alkyl
- R 5 is selected from the group consisting of -O- and N-R 51 ;
- R 51 is selected from the group consisting of hydrogen and Ci-C 6 alkyl optionally substituted with 1-3 substituents selected from the group consisting of keto, halo, amino, hydroxy, cyano, nitro, -N 3 , and -C0 2 H or an ester thereof;
- C 14 content of a compound of Formula (I), that is tabernanthine, ibogamine, ibogaline, ibogamine, and noribogaine is less than 0.9 ppt, preferably less than
- the compound of Formula (I) excludes a compound selected from Iboga alkaloids.
- Iboga alkaloids are alkaloids, isolated from the plant Tabernanthe Iboga that contain a tryptamine and an isoquinuclidene moiety as present in ibogaine or noribogaine.
- the excluded iboga alkaloid is
- the compound of Formula (I) is of Formula (I A) or (IB):
- R 1 , R 2 , R 4 , and R 5 are defined as in Formula (I) above.
- the compound of Formula (I) is of Formula (IIIA) or (IIIB):
- R 1 , R 3 , R 4 , and R 5 are defined as in Formula (I) above.
- the compound of Formula (I) is of Formula (IV A) or (IVB):
- R is selected from the group consisting of hydrogen and Ci-C 6 alkyl optionally substituted with 1-3 substituents selected from the group consisting of halo, amino, hydroxy, cyano, nitro, -N 3 , -C0 2 H or an ester thereof, and phenyl optionally substituted with 1-3 substituents selected from the group consisting of Ci-C 6 alkyl and Ci- C 6 alkoxy;
- k 1 or 2;
- R 1 , R 2 , R 3 , R 4 , and R 5 are defined as in Formula (I) above.
- the compound of Formula (I) is of Formula (IVC), (IVD (VIA), or (VIB):
- R 11 is selected from the group consisting of hydrogen and Ci-C 6 alkyl optionally substituted with 1-3 substituents selected from the group consisting of halo, amino, hydroxy, cyano, nitro, -N 3 , and -C0 2 H or an ester thereof, and phenyl optionally substituted with 1-3 substituents selected from the group consisting of Ci-C 6 alkyl and C ⁇ - C 6 alkoxy;
- k 1 or 2;
- R 2 , R 3 , R 4 , and R 5 are defined as in Formula (I) above.
- the present invention provides compounds of formula (VA):
- this invention provides a compound of Formula (VIC): as tabulated below.
- Me, Et, Pr, Bu and Bn refer to methyl, ethyl, propyl, butyl, and benzyl, respectively.
- this invention provides an isolated enantiomer of a compound of any one of Formulas (I), (IA), (IB), (IIA), (IIB), (IIIA), (IIIB), (IVA), (IVB), (IVC), (IVD), (VA), (VI), (VIA), (VIB), or (VIC) in substantial enantiomeric excess.
- this invention provides a compound of formula:
- R 2 is hydrogen.
- R 1 is methyl or benzyl.
- the compound is provided as an isolated enantiomer in substantial enantiomeric excess.
- this invention provides (+) noribogaine.
- the (+) noribogaine has a 14 C content of less than 1 ppt, preferably less than 0.9 ppt, and more preferably less than 0.8 ppt.
- 14 C has a half-life of about 5,730 years and is generated in the upper atmosphere as 14 C0 2 .
- the amount of 14 C0 2 present is approximately 1 ppt (parts per trillion) and, through photosynthesis, accumulates in plants resulting in a 14 C content of plant material of approximately 1 ppt. Accordingly, plant derived compounds are expected to have approximately 1 ppt 14 C.
- the synthetic compounds disclosed herein are derived from fossil fuels, which, due to 14 C decay, would have a 14 C content of less than 1 ppt 14 C.
- synthetic indole and benzofuran fused isoquinuclidene derivative having a 14 C content of less than 1 ppt, preferably, less than 0.90 ppt, or more preferably less than 0.8 ppt.
- k, R , R , R , and R are defined as in any aspect or embodiment herein.
- Compound i is obtained, following the procedure described in U.S. application no. 13/ 358,446, which is incorporated herein in its entirety by reference.
- Compound ii is available commercially or prepared easily from commercially available material following steps well known in the art.
- this invention provides a process for preparing compound iii comprising contacting compound i with compound ii under conditions to provide compound iii. Accordingly, in step 1, compound i is coupled with compound ii, preferably in an inert solvent, in the presence of an amide or an ester coupling reagent.
- the reaction is carried out at 0-50°C for a period of time sufficient to provide a substantial amount of the product, which can be ascertained by using routine methods such as thin layer chromatography, 1 H-nuclear magnetic resonance (NMR) spectroscopy, and the likes.
- the product can be isolated and optionally purified using standard purification techniques, such as liquid chromatography, crystallization, and precipitation, or the products may be used for a subsequent reaction without further purification.
- this invention provides a process for preparing compound iv comprising subjecting compound iii under conditions to provide compound iv. Accordingly, in step 2, compound iii is made to undergo an intramolecular Heck type cylization, preferably in an inert solvent, in the presence of 100-130 mole%, with respect to compound iii, of a Pd(II) salt, and an oxidant such as a silver (I).
- a reducing agent such as a borohydride is used to reductively workup the reaction mixture to provide compound iv.
- the reaction is carried out at 30-90°C for a period of time sufficient to provide a substantial amount of the product, which can be ascertained by using routine methods such as thin layer chromatography, NMR spectroscopy, and the likes.
- the product can be isolated and optionally purified using standard purification techniques, such as liquid chromatography, crystallization, and precipitation, or the products may be used for a subsequent reaction without further purification.
- this invention provides a process for preparing compound vi comprising contacting compound v with R 4 -M, wherein R 4 is Ci-C 6 alkyl, C2-C 6 alkenyl, or C3-C 6 alkynyl, optionally substituted with a protected form of amino or hydroxy, and M is lithium or magnesium halide, under conditions to provide compound vi.
- step 3 compound v, which is compound iv wherein C(R 4 ) 2 is a keto group, and which is readily obtained from compound iv, where C(R 4 ) 2 is a cyclic ketal or thioketal by deprotection, is reacted with an R 4 anion equivalent, R 4 -M, wherein M is lithium, a magnesium halide, and the like.
- the reaction is carried out, preferably with about a 10 fold excess of the R 4 -M in an inert solvent such as ether or tetrahydrofuran at a temperature of -5°C to 15°C for a period of time sufficient to provide a substantial amount of the product, which can be ascertained by using routine methods such as thin layer chromatography, 1 H-nuclear magnetic resonance (NMR) spectroscopy, and the likes.
- NMR 1 H-nuclear magnetic resonance
- this invention provides a process for preparing compound vii comprising subjecting compound vi under conditions to provide compound vii.
- step 4 compound vi is dehydrated, preferably using an acid such as a sulfonic acid to provide compound vii.
- the dehydration is carried out in an inert solvent, preferably at a temperature where the solvent refluxes, for a period of time sufficient to provide a substantial amount of the product, which can be ascertained by using routine methods such as thin layer chromatography, NMR spectroscopy, and the likes.
- routine methods such as thin layer chromatography, NMR spectroscopy, and the likes.
- solvents useful for this purpose is well known in the art and will be apparent to the skilled artisan upon reading this disclosure.
- the product can be isolated and optionally purified using standard purification techniques, such as liquid chromatography, crystallization, and precipitation, or the products may be used for a subsequent reaction without further purification.
- this invention provides a process for preparing compound viii comprising subjecting compound vii under conditions to provide compound viii.
- step 5 the amide carbonyl of compound vii is reduced to a -CH 2 - moiety by reacting with a borohydride, optionally activated with a Lewis acid, such as BF 3 etherate, or with an aluminum hydride.
- the reaction is performed in an inert solvent, preferably, an ether or tetrahydrofuran at a temperature of 0-50°C or in a refluxing solvent.
- the reaction is carried out for a period of time sufficient to provide a substantial amount of the product, which can be ascertained by using routine methods such as thin layer chromatography, NMR spectroscopy, and the likes.
- the product can be isolated and optionally purified using standard purification techniques, such as liquid chromatography, crystallization, and precipitation, or the products may be used for a subsequent reaction without further purification.
- this invention provides a process for preparing compound ix comprising subjecting compound viii under conditions to provide compound ix. Accordingly, in step 6, compound viii is hydrogenated to provide compound viii. The hydrogenation is carried out using Pd or Pt or their oxides or hydroxides adsorbed on a solid support such as carbon, alumina, and the like, preferably in an amount less than 100 mole % with respect to compound viii, and hydrogen.
- the hydrogenation is carried out in an inert solvent, such as an alcohol, ethyl acetate, or an ether, at 15-30°C for a period of time sufficient to provide a substantial amount of the product, which can be ascertained by using routine methods such as thin layer chromatography, NMR spectroscopy, and the likes.
- an inert solvent such as an alcohol, ethyl acetate, or an ether
- the product can be isolated and optionally purified using standard purification techniques, such as liquid chromatography, crystallization, and precipitation.
- C(R 4 ) 2 is ia cyclic ketal or thioketal.
- R 5 is NH.
- R 5 is O.
- R 4 is Ci-C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl, optionally substituted with 1-3 substituents, as provided herein, or their protected forms that will be apparent to the skilled artisan.
- this invention provides processes, preferably, enantioselective processes, for preparing (-) noribogaine, in a substantially enantiomerically pure form, as schematically illustrated below, where the reagents indicated are merely illustrative and are not limiting, as discussed in further detail below.
- this invention provides a process for preparing compound 2 comprising contacting compound 1 with 5-benzyloxyindoleacetic acid under conditions to provide compound 2.
- Compound 1 is coupled with the benzyloxy substituted indole acetic acid to provide compound 2.
- the coupling is performed preferably in an inert solvent, such as a chlorinated solvent such as dichloromethane, or in tetrahydrofuran, or acetonitrile, in the presence of a amide or ester coupling reagent.
- the coupling is performed in the presence of l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) and a hindered base, such as diisopropylethyl amine (DIPEA).
- EDCI l-ethyl-3-(3-dimethylaminopropyl)carbodiimide
- DIPEA diisopropylethyl amine
- the reaction is carried out at 0-50°C for a period of time sufficient to provide a substantial amount of the product, which can be ascertained by using routine methods such as thin layer
- FIG. 3 demonstrates the 1 H-NMR spectrum of compound 2.
- the product can be isolated and optionally purified using standard purification techniques, such as liquid chromatography, crystallization, and precipitation, or the product may be used for a subsequent reaction without further purification.
- this invention provides a process for preparing compound 3 comprising subjecting compound 2 under conditions to provide compound 3.
- step 2 compound 2 is deprotected by reacting with an aqueous acid.
- Various mineral acids such as sulfuric acid or hydrochloric acid, and sulfonic acids, such as toluene sulfonic acid are useful as the acid.
- the deprotected compound is subjected to an intramolecular Heck type cylization.
- Various art known palladium reagents such as palladium chloride and complexes thereof (such as the bis acetonitrile complex) are useful as the cyclization reagent, used in 100-130 mole% with respect to compound 2, further in presence of an oxidant, such as a Ag(I) salt. Reductive workup, employing a borohydride was demonstrated to provide compound 3 (see, FIG. 1).
- the reaction is carried out in an inert solvent, such as acetonitrile, alcohols, acetic acid, and mixtures thereof, at 30-90°C, preferably at 60-80°C for a period of time sufficient to provide a substantial amount of the product, which can be ascertained by using routine methods such as thin layer chromatography, NMR spectroscopy, and the likes.
- an inert solvent such as acetonitrile, alcohols, acetic acid, and mixtures thereof
- the product can be isolated and optionally purified using standard purification techniques, such as liquid chromatography, crystallization, and precipitation, or the product may be used for a subsequent reaction without further purification.
- this invention provides a process for preparing compound 4 comprising contacting compound 3 with an ethyl anion equivalent under conditions to provide compound 4.
- an ethyl anion equivalent is an anion that after this reaction is easily converted to an ethyl group.
- compound 3 is reacted with an ethyl anion equivalent, such as, vinyl magnesium bromide (in a 10 fold mole/mole excess with respect to compound 3), in ether, tetrahydrofuran or a mixture thereof to provide after aqueous work up, compound 4.
- the reaction is carried out for a period of time sufficient to provide a substantial amount of the product, which can be ascertained by using routine methods such as thin layer chromatography, NMR
- the product can be isolated and optionally purified using standard purification techniques, such as liquid chromatography, crystallization, and precipitation, or the product may be used for a subsequent reaction without further purification.
- this invention provides a process for preparing compound 5 comprising subjecting compound 4 under conditions to provide compound 5.
- compound 4 is dehydrated to provide compound 5.
- the dehydration is performed preferably using an acid such as a sulfonic acid such as toluene sulfonic acid to provide compound vii.
- the dehydration is carried out in an inert solvent, preferably at a temperature where the solvent refluxes, for a period of time sufficient to provide a substantial amount of the product, which can be ascertained by using routine methods such as thin layer chromatography, NMR spectroscopy, and the likes.
- Various solvents useful for this purpose is well known in the art and will be apparent to the skilled artisan upon reading this disclosure.
- the product can be isolated and optionally purified using standard purification techniques, such as liquid chromatography, crystallization, and precipitation, or the product may be used for a subsequent reaction without further purification.
- this invention provides a process for preparing compound 6 comprising subjecting compound 5 under conditions to provide compound 6.
- step 5 the amide carbonyl of compound 5 is reduced to provide compound 6, by reacting with a borohydride, optionally activated with a Lewis acid, such as BF 3 etherate, or with an aluminum hydride.
- a preferred reagent is lithium aluminum hydride.
- the reaction is performed in an inert solvent, preferably, an ether or tetrahydrofuran at a temperature of 0-50°C or in a refluxing solvent.
- the reaction is carried out for a period of time sufficient to provide a substantial amount of the product, which can be ascertained by using routine methods such as thin layer chromatography, NMR spectroscopy, and the likes.
- the product can be isolated and optionally purified using standard purification techniques, such as liquid chromatography, crystallization, and precipitation, or the product may be used for a subsequent reaction without further purification.
- this invention provides a process for preparing (-) noribogaine or a salt thereof comprising subjecting compound 6 under conditions to provide (-) noribogaine or a salt thereof.
- step 6 compound 6 is hydrogenated to provide (-) noribogaine or a salt thereof.
- the hydrogenation is carried out using Pd, Pt, Rh or their oxides or hydroxides adsorbed on a solid support such as carbon, alumina, and the like, preferably in an amount less than 100 mole % with respect to compound 6, and hydrogen.
- a preferred reagent is Pt0 2 .
- the hydrogenation is carried out in an inert solvent, such as an alcohol, ethyl acetate, or an ether.
- the hydrogenation is carried out at 15-30°C for a period of time sufficient to provide a substantial amount of the product, which can be ascertained by using routine methods such as thin layer chromatography, NMR spectroscopy, and the likes.
- the product can be isolated and optionally purified using standard purification techniques, such as liquid chromatography, crystallization, and precipitation.
- the reactions are carried out, preferably in an inert solvent that will be apparent to the skilled artisan upon reading this disclosure, and at temperatures that will also be apparent to the skilled artisan upon reading this disclosure.
- the reactions are performed for a period of time sufficient to provide a substantial amount of the product, which can be ascertained by using routine methods such as thin layer chromatography, 1 H-nuclear magnetic resonance (NMR) spectroscopy, and the likes.
- the products can be isolated and optionally purified using standard purification techniques, such as liquid chromatography, crystallization, precipitation, and distillation under reduced pressure, or the products may be used for a subsequent reaction without further purification.
- this invention provides a process for preparing a compound of formula:
- TBS silicon protecting group
- Benzoquinone is combined with, e.g., at least an equimolar amount of the diene in an inert chlorinated solvent in presence of a catalytic amount, preferably 20%-35% molar amount, still more preferably, 25%-30% molar amount with respect to benzoquinone, of Ti((S)-binol)Cl 2 .
- the concentration of the reactants and the catalyst in the reaction solvent are as follows: benzoquinone, 0.05-0.2 molar, preferably 0.09-0.13 molar, still more preferably 0.1 1 molar: diene, 0.05-0.2 molar, preferably 0.1-0.14 molar, still more preferably 0.12 molar; and the catalyst, 0.01- 0.1 molar, preferably 0.02-0.06 molar, still more preferably 0.03 molar.
- the reaction is performed at room temperature for a period of time sufficient to effect a substantial completion of the reaction.
- this invention provides a process for preparing a compound of formula:
- Ti((S)-binol)Cl 2 or Ti((S)-binol)Cl 2 is preferably prepared in situ by reacting (R) or (S)-binol with Ti(- OCHMe 2 )2Cl 2 .
- this invention provides a process for preparing a compound of formula:
- the reducing agent is diisobutylaluminum hydride.
- this invention provides a process for preparing a compound of formula:
- R S S0 2 C1 wherein R s is alkyl, fluoroalkyl, aryl, or aryl substiotuted with an alkyl or a halogen group, a base, and optionally a nucleophilic catalyst such as 4- N,N-dialkylaminopyridine to provide a compound of formula:
- R S S0 2 C1 wherein R s is alkyl, fluoroalkyl, aryl, or aryl substituted with an alkyl or a halogen group, a base, and optionally a 4-N,N-dialkylaminopyridine to provide a compound of formula:
- Steps (i) to (x) can be performed substantially according to the methods described in White, supra.
- the hydrogenation is performed preferably employing a catalyst such Rh/Al 2 0 3 and hydrogen, which catalyst does not produce substantial amounts of the hydrogenolyzed product.
- the allylic hydroxy group(s) can be replaced by hydrogen atom(s).
- a variety of oxidizing agents can be employed for step (ii) such as for example pyridinum dichromate, pyridinium chlorochromate, and the like. Those oxidizing agents are preferred that would not convert the tributylsilyloxy (OTB S) group to an -OH group.
- step (iii) The selective ketalization of the less hindered ketone in step (iii) is performed using a mild acid catalyst such as pyridinium para tolune sulfonate (PPTS).
- a salt of NH 2 OH is reacted with the ketone and a base to provide the oxime.
- bases may be employed, including without limitation, acetates, preferably alkali metal acetates, alkali, and nitrogen containing bases such as pyridine, triethyl amine and the like.
- step (vi) a variety of sulfonyl chlorides may be used, including without limitation para toluene sulfonyl chloride.
- a variety of bases may be employed, including without limitation, alkali and nitrogen containing bases such as pyridine, triethyl amine and the like.
- Preferred nucleophilic catalysts include 4-N,N-dimethylaminopyridine and 4-pyrrolidinopyridine.
- fluoride sources may be used including tertiary alkyl ammonium fluorides, such a tetrabutylammonium fluoride.
- a variety of bases may be employed, including without limitation, alkali and nitrogen containing bases such as pyridine, triethyl amine and the like.
- Preferred nucleophilic catalysts include 4-N,N- dimethylaminopyridine and 4-pyrrolidinopyridine.
- preferred non- nucleophilic bases used include, hydrides such as sodium, potassium and calcium hydrides.
- a variety of acids can be used to convert the dimethyl ketal to the ketone.
- chromatography Depending on the amount of impurity present, a product may be separated by column chromatography, crystallization, or such other techniques well known to the skilled artisan, or the reaction product may be used without further purification in the next step.
- this invention provides a process for converting:
- this invention provides a process for preparing a compound of formula:
- R 1 is C 1 -C 4 alkyl optionally substituted with 1-3 phenyl or substituted phenyl groups, wherein the substituted phenyl is substituted with 1-3 C1-C4 alkyl or C1-C4 alkoxy groups, under Fischer indole synthesis conditions to provide the keto ibogaine derivative of formula:
- R is methyl.
- R is a methyl group substituted with 1-3, preferably 1-2, more preferably 1 phenyl group, which phenyl group is optionally substituted with 1-3 C1-C4 alkyl or C1-C4 alkoxy groups.
- R is benzyl.
- R is methyl, it is preferred to not use a boron based Lewis acid, such as BF 3 etherate, for this transformation.
- the ketoamide compound is present at least 80%, preferably at least 90%, more preferably at least 95%, or still more preferably at least 98% as the (5aR,7R,9S,9aS)-9-ethyl-3,4,5a,6,7,8,9,9a-octahydro-l,7-methano-lH- benz [b] azepine-2,5 -dione enantiomer :
- the ketoamide compound contains, at least 60%>, preferably at least 80%>, more preferably at least 90%, or still more preferably at least 96% ee of the
- keto ibogaine derivative is present at least 80%, preferably at least 90%, more preferably at least 95%, or still more preferably at least 98% as the 2(R), 4(S), 5(S), 6(S) and 18(R) enantiomer.
- a substituted hydrazine containing an electron donating 4- alkoxy substituent effectively provides the tricyclic indole under Fischer indole synthesis conditions.
- the ketoamide compound is combined with at least an equimolar amount of the substituted phenylhydrazme or a salt thereof, in the presence of an acid or a mixture of acids.
- Suitable acids include carboxylic Bronsted acids such as acetic acid and Lewis acids such as BF and its solvates such as etherates.
- the reaction is performed at 40°C- 60°C, and may optionally be warmed up to 70°C-90°C, for a period of time sufficient to effect a substantial completion of the reaction.
- Suitable solvent include acetic acid, propionic acid and the like.
- Suitable salts of the substituted phenylhydrazme include salts of mineral acids, such as HC1.
- this invention provides a method of synthesis comprising contacting a ketoamide compound of formula:
- R 1 is C 1 -C 4 alkyl optionally substituted with 1-3 phenyl or substituted phenyl groups, wherein the substituted phenyl is substituted with 1-3 C 1 -C 4 alkyl or C 1 -C 4 alkoxy groups, under Fischer indole synthesis conditions to provide a keto ibogaine derivative of formula:
- the ketoamide compound is present at least 80%, preferably at least 90%, more preferably at least 95%, or still more preferably at least 98% as the (5aS,7S,9R,9aR)-9-ethyl-3,4,5a,6,7,8,9,9a-octahydro-l,7-methano-lH- benz [b] azepine-2,5 -dione enantiomer :
- the keto ibogaine derivative is present at least 80%, preferably at least 90%), more preferably at least 95%, or still more preferably at least 98%> as the 2(S), 4(R), 5(R), 6(R) and 18(S) enantiomer.
- the process further comprises subjecting the keto ibogaine derivative:
- the keto ibogaine derivative is contacted with at least an equimolar, preferably 4-6 molar excess of a borohydride, preferably NaBH 4 and a Lewis acid, preferably, BF 3 etherate, in an inert solvent such as tetrahydrofuran.
- a borohydride preferably NaBH 4
- a Lewis acid preferably, BF 3 etherate
- the reaction is performed initially at 0°C and then at room temperature for a a period of time sufficient to effect a substantial completion of the reaction.
- the process further comprises subjecting the keto ibogaine derivative:
- the process further comprises deprotecting the compound of formula:
- the noribogaine obtained is present at least 80%, preferably at least 90%, more preferably at least 95%, or still more preferably at least 98% as the (-) or naturally occurring 2(R), 4(S), 5(S), 6(S) and 18(R) enantiomer of noribogaine.
- R 1 is C1-C4 alkyl, and the deprotection is performed by using BBr 3 in an inert solvent under conditions well known to the skilled artisan.
- R 1 is benzyl and the deprotection is performed by using
- the process further comprises deprotecting the compound of formula:
- the noribogaine obtained is present at least 80%, preferably at least 90%, more preferably at least 95%, or still more preferably at least 98%o as the (+) or nonnatural 2(S), 4(R), 5(R), 6(R) and 18(S) enantiomer of noribogaine.
- this invention provides (-) noribogaine and (+)noribogaine, and intermediates thereto, preferably in substantially enantiomerically pure forms, prepared according to the processes provided herein.
- the indole isoquinuclidene derivative (-) noribogaine has utility in the treatment of drug dependency and as an analgesic. See U.S. Patent Nos. 6,348,456 7,220,737, supra.
- the indole and benzofuran fused isoquinuclidene derivatives provided and (+) noribogaine herein have utility to test their interaction with the opioid receptors to better understand the mechanism of (-) noribogaine 's analgesic action.
- the novel compounds provided herein also have utility as intermediates to synthetic noribogaine or as compounds having activity in drug dependency or as analgesics.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261741798P | 2012-01-25 | 2012-01-25 | |
US201261590740P | 2012-01-25 | 2012-01-25 | |
US201261591258P | 2012-01-26 | 2012-01-26 | |
PCT/US2012/022787 WO2013112163A1 (fr) | 2012-01-25 | 2012-01-26 | Dérivés d'isoquinuclidène fusionnés à de l'indole et du benzofurane et procédés de préparation de ceux-ci |
PCT/US2013/023017 WO2013112757A1 (fr) | 2012-01-25 | 2013-01-24 | Dérivés d'isoquinuclidène réunis par fusion à de l'indole et du benzofurane et leurs procédés de préparation |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2807167A1 true EP2807167A1 (fr) | 2014-12-03 |
EP2807167A4 EP2807167A4 (fr) | 2016-01-20 |
Family
ID=48873918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13741381.1A Withdrawn EP2807167A4 (fr) | 2012-01-25 | 2013-01-24 | Dérivés d'isoquinuclidène réunis par fusion à de l'indole et du benzofurane et leurs procédés de préparation |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2807167A4 (fr) |
CA (1) | CA2858105A1 (fr) |
WO (1) | WO2013112757A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11840541B2 (en) * | 2014-11-26 | 2023-12-12 | The Trustees Of Columbia University In The City Of New York | Opioid receptor modulators |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
AU2020259406A1 (en) | 2019-04-17 | 2021-11-04 | Compass Pathfinder Limited | Treatment of depression and other various disorders with psilocybin |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7220737B1 (en) * | 1997-09-04 | 2007-05-22 | Novoneuron, Inc | Noribogaine in the treatment of pain and drug addiction |
JP5542972B2 (ja) * | 2010-02-22 | 2014-07-09 | ザ スクリプス リサーチ インスティテュート | Mdrがん細胞に対する強化された生物活性を提供する10’−フッ素化ビンカアルカロイド |
RU2586296C2 (ru) * | 2010-07-23 | 2016-06-10 | Демеркс, Инк. | Композиции норибогаина |
CA3122767C (fr) * | 2011-12-08 | 2023-03-28 | Demerx, Inc. | Synthese totale stereoselective de noribogaine |
EP2807168A4 (fr) * | 2012-01-25 | 2015-10-14 | Demerx Inc | Voacangine synthétique |
-
2013
- 2013-01-24 EP EP13741381.1A patent/EP2807167A4/fr not_active Withdrawn
- 2013-01-24 WO PCT/US2013/023017 patent/WO2013112757A1/fr active Application Filing
- 2013-01-24 CA CA2858105A patent/CA2858105A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2858105A1 (fr) | 2013-08-01 |
EP2807167A4 (fr) | 2016-01-20 |
WO2013112757A1 (fr) | 2013-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
May et al. | The structural and synthetic implications of the biosynthesis of the calycanthaceous alkaloids, the communesins, and nomofungin | |
US20160024075A1 (en) | Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them | |
KR100400941B1 (ko) | 축합6환화합물및그의제조방법 | |
AU2012209332B2 (en) | Methods and compositions for preparing noribogaine from voacangine | |
CA2858820C (fr) | Voacangine synthetique | |
Schwartz et al. | Host-guest complexation. 65. Six new saddle shaped hosts based on fused dibenzofuran units | |
FR2790474A1 (fr) | Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique | |
TWI831507B (zh) | 用於製備mcl1抑制劑之程序及中間物 | |
CA2989550C (fr) | Derives d'indole et de benzofurane halogenes d'isoquinuclidene et procedes pour leur preparation. | |
WO2013112757A1 (fr) | Dérivés d'isoquinuclidène réunis par fusion à de l'indole et du benzofurane et leurs procédés de préparation | |
WO2013112163A1 (fr) | Dérivés d'isoquinuclidène fusionnés à de l'indole et du benzofurane et procédés de préparation de ceux-ci | |
CA2857969A1 (fr) | (1r,4r) 7-oxo-2-azabicyclo[2.2.2]oct-5-ene et ses derives | |
JP6733449B2 (ja) | ベルベリン型アルカロイドの製造方法 | |
AU2002248764B2 (en) | Synthesis of silyl camptothecins and silyl homocamptothecins | |
AU2002248764A1 (en) | Synthesis of silyl camptothecins and silyl homocamptothecins | |
Eberlin et al. | Novel applications of polyfunctionalised organoboron and nitroso compounds | |
Schulz et al. | Heterogeneously Catalyzed Diastereoselective Synthesis of 2-Nitro-1, 3-di (pyridin-2-yl) propane-1, 3-diols | |
KR101327720B1 (ko) | 이리노테칸의 제조방법 | |
Edwankar | Part I: The first regio-and atropdiastereoselective total synthesis of the dimeric indole alkaloid (+)-dispegatrine, as well as the first total synthesis of the sarpagine alkaloids (+)-spegatrine, lochvinerine,(+)-lochneram and an improved total synthesis of (+)-10-methoxyvellosimine,(+)-lochnerine and (+)-sarpagine. Part II: Studies directed toward the total synthesis of the carbon-19 methyl substituted sarpagine-macroline alkaloids (+)-macro-salhine chloride as well as macrocarpine A, B and C | |
Voûte | Rearrangements in the Indolo [2, 3-b] quinoline System: A Novel Approach to the Synthesis of Perophoramidine and the Communesins | |
Gupta | Model studies toward the total synthesis of thebaine by an intramolecular cycloaddition strategy | |
Calvert | From CH Activation to Biomimetic Synthesis: The Construction and Reconstruction of Yuremamine | |
TW202421612A (zh) | 用於製備mcl1抑制劑之程序及中間物 | |
Dwight | The Synthesis and Biological Activity of 2'-Fluoro-N-methanocarbathymidine Epimers and An Approach Towards the Synthesis of Morphine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140820 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 451/04 20060101AFI20151210BHEP Ipc: C07D 495/10 20060101ALI20151210BHEP Ipc: A61K 31/46 20060101ALI20151210BHEP Ipc: C07D 491/10 20060101ALI20151210BHEP |
|
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20151221 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20170131 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20171101 |